JP6243333B2 - ワクシニアウィルスの生成のための方法および組成物 - Google Patents

ワクシニアウィルスの生成のための方法および組成物 Download PDF

Info

Publication number
JP6243333B2
JP6243333B2 JP2014524110A JP2014524110A JP6243333B2 JP 6243333 B2 JP6243333 B2 JP 6243333B2 JP 2014524110 A JP2014524110 A JP 2014524110A JP 2014524110 A JP2014524110 A JP 2014524110A JP 6243333 B2 JP6243333 B2 JP 6243333B2
Authority
JP
Japan
Prior art keywords
cell
vaccinia virus
virus
culture
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014524110A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014521353A5 (cg-RX-API-DMAC7.html
JP2014521353A (ja
Inventor
デービッド キルン
デービッド キルン
ジョン ベル
ジョン ベル
Original Assignee
シラジェン バイオセラピューティクス インコーポレイテッド
シラジェン バイオセラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シラジェン バイオセラピューティクス インコーポレイテッド, シラジェン バイオセラピューティクス インコーポレイテッド filed Critical シラジェン バイオセラピューティクス インコーポレイテッド
Publication of JP2014521353A publication Critical patent/JP2014521353A/ja
Publication of JP2014521353A5 publication Critical patent/JP2014521353A5/ja
Application granted granted Critical
Publication of JP6243333B2 publication Critical patent/JP6243333B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2014524110A 2011-08-05 2012-08-03 ワクシニアウィルスの生成のための方法および組成物 Active JP6243333B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161515724P 2011-08-05 2011-08-05
US61/515,724 2011-08-05
PCT/US2012/049550 WO2013022764A1 (en) 2011-08-05 2012-08-03 Methods and compositions for production of vaccina virus

Publications (3)

Publication Number Publication Date
JP2014521353A JP2014521353A (ja) 2014-08-28
JP2014521353A5 JP2014521353A5 (cg-RX-API-DMAC7.html) 2016-10-20
JP6243333B2 true JP6243333B2 (ja) 2017-12-06

Family

ID=46650950

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014524110A Active JP6243333B2 (ja) 2011-08-05 2012-08-03 ワクシニアウィルスの生成のための方法および組成物

Country Status (12)

Country Link
US (3) US9719105B2 (cg-RX-API-DMAC7.html)
EP (1) EP2739293B1 (cg-RX-API-DMAC7.html)
JP (1) JP6243333B2 (cg-RX-API-DMAC7.html)
KR (1) KR102022952B1 (cg-RX-API-DMAC7.html)
CN (1) CN103732236B (cg-RX-API-DMAC7.html)
AU (1) AU2012294606B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014000787B1 (cg-RX-API-DMAC7.html)
CA (1) CA2841831C (cg-RX-API-DMAC7.html)
DK (1) DK2739293T3 (cg-RX-API-DMAC7.html)
ES (1) ES2813413T3 (cg-RX-API-DMAC7.html)
PL (1) PL2739293T3 (cg-RX-API-DMAC7.html)
WO (1) WO2013022764A1 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3190510A1 (en) 2014-07-16 2016-01-21 Transgene Sa Oncolytic virus for expression of immune checkpoint modulators
US20180028626A1 (en) 2015-02-13 2018-02-01 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
EP3310383B1 (en) * 2015-06-19 2020-02-19 Sillajen, Inc. Compositions and methods for viral embolization
CN106676071B (zh) * 2015-11-06 2019-07-19 天士力创世杰（天津）生物制药有限公司 HeLa-F细胞及其用途
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
WO2018122088A1 (en) 2016-12-28 2018-07-05 Transgene Sa Oncolytic viruses and therapeutic molecules
WO2018195552A1 (en) 2017-04-21 2018-10-25 Sillajen, Inc. Oncolytic vaccinia virus and checkpoint inhibitor combination therapy
WO2018234506A2 (en) 2017-06-21 2018-12-27 Transgene Sa PERSONALIZED VACCINE
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
EP3973973A1 (en) 2017-10-31 2022-03-30 KaliVir Immunotherapeutics, Inc. Platform oncolytic vector for systemic delivery
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
EP3617230A1 (en) 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
EP3884044A4 (en) * 2018-11-21 2022-08-31 Western Oncolytics Ltd. MANUFACTURE OF VIRUSES
AU2019412516A1 (en) 2018-12-28 2021-07-15 Transgene M2-defective poxvirus
KR102228267B1 (ko) 2019-01-25 2021-03-17 바이로큐어 주식회사 Bhk-21 세포를 이용한 바이러스 생산방법
CN112143693B (zh) * 2019-06-28 2024-12-27 杭州康万达医药科技有限公司 一种生产病毒的方法及收获液组合物
EP3842065A1 (en) 2019-12-23 2021-06-30 Transgene Process for designing a recombinant poxvirus for a therapeutic vaccine
KR20230027070A (ko) * 2020-06-22 2023-02-27 코오롱생명과학 주식회사 부유세포를 이용한 백시니아 바이러스의 대량 생산 방법
EP4178605A1 (en) 2020-07-13 2023-05-17 Transgene Treatment of immune depression
AU2021385059A1 (en) 2020-11-19 2023-06-08 Kalivir Immunotherapeutics, Inc. Oncolytic immunotherapy by tumor micro-environment remodeling
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager
CR20230551A (es) 2021-04-30 2024-05-07 Kalivir Immunotherapeutics Inc Virus oncolíticos para la expresión modificada del mhc
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
TW202321458A (zh) 2021-09-22 2023-06-01 瑞典商生物創新國際公司 新穎抗體組合及其用途
GB2614309A (en) 2021-12-24 2023-07-05 Stratosvir Ltd Improved vaccinia virus vectors
CN114395538A (zh) * 2022-01-19 2022-04-26 和元生物技术（上海）股份有限公司 一种促进重组病毒载体向细胞外分泌的方法
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
JP2025523573A (ja) 2022-07-01 2025-07-23 トランジェーヌ サーファクタントタンパク質－ｄとｔｎｆｓｆのメンバーを含んでなる融合タンパク質
KR20250052416A (ko) 2022-08-18 2025-04-18 트랜스진 키메라 폭스바이러스
WO2024188802A1 (en) * 2023-03-10 2024-09-19 Bavarian Nordic A/S Methods of isolating poxviruses from avian cell cultures

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267965B1 (en) * 1981-12-24 2001-07-31 Virogenetics Corporation Recombinant poxvirus—cytomegalovirus compositions and uses
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US7445924B2 (en) * 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
NZ524661A (en) * 2000-11-23 2005-03-24 Bavarian Nordic As Modified vaccinia ankara virus variant
EP2269618A1 (en) 2002-08-12 2011-01-05 Jennerex Biotherapeutics ULC An oncolytic vaccinia virus for use in combination with a chemotherapy for treating cancer.
EP1869171B2 (en) * 2005-04-11 2015-10-14 Crucell Holland B.V. Virus purification using ultrafiltration
WO2007030668A2 (en) * 2005-09-07 2007-03-15 Jennerex Biotherapeutics Ulc Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
WO2008018411A1 (en) * 2006-08-07 2008-02-14 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Method for production of live smallpox vaccine
KR20080084528A (ko) * 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
US8003364B2 (en) * 2007-05-14 2011-08-23 Bavarian Nordic A/S Purification of vaccinia viruses using hydrophobic interaction chromatography
WO2009048769A2 (en) * 2007-10-10 2009-04-16 Kirin Pharma Kabushiki Kaisha Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same
EP2085092A1 (en) * 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Attenuated oncolytic paramyxoviruses encoding avian cytokines
JP2013500717A (ja) 2009-07-28 2013-01-10 コーニング インコーポレイテッド 細胞を培養するための合成マイクロキャリア
JP5879266B2 (ja) * 2009-09-14 2016-03-08 シラジェン バイオセラピューティクス インコーポレイテッド 腫瘍崩壊性ワクシニアウイルスの併用癌療法

Also Published As

Publication number Publication date
CA2841831A1 (en) 2013-02-14
US9719105B2 (en) 2017-08-01
US20170298324A1 (en) 2017-10-19
CA2841831C (en) 2019-12-31
US10767166B2 (en) 2020-09-08
US20140162342A1 (en) 2014-06-12
KR20140058601A (ko) 2014-05-14
ES2813413T3 (es) 2021-03-23
AU2012294606A1 (en) 2014-01-23
EP2739293A1 (en) 2014-06-11
EP2739293B1 (en) 2020-06-10
BR112014000787B1 (pt) 2021-04-13
CN103732236A (zh) 2014-04-16
PL2739293T3 (pl) 2020-11-16
CN103732236B (zh) 2017-09-15
KR102022952B1 (ko) 2019-09-20
US20190169578A1 (en) 2019-06-06
JP2014521353A (ja) 2014-08-28
AU2012294606B2 (en) 2016-10-06
BR112014000787A2 (pt) 2017-07-11
US10202581B2 (en) 2019-02-12
WO2013022764A1 (en) 2013-02-14
DK2739293T3 (da) 2020-08-24

Similar Documents

Publication Publication Date Title
JP6243333B2 (ja) ワクシニアウィルスの生成のための方法および組成物
US10329536B2 (en) Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an MDCK cell suspension culture
KR100968141B1 (ko) 세포 배양물에서 바이러스의 증식 방법
US10851350B1 (en) Bioreactor production of virus from adherent cells
EP3006562B1 (en) Mdck-derived cell strain suspension-cultured in protein-free medium and method for proliferating virus using cell strain
JP2025118611A (ja) 接着細胞からのウイルスのバイオリアクター生成
CN111662883A (zh) 一种制备及纯化溶瘤病毒的方法及重组溶瘤弹状病毒
HK1194296B (en) Methods and compositions for production of vaccina virus
HK1194296A (en) Methods and compositions for production of vaccina virus
MX2013001772A (es) Linea celular de amniocitos humanos permanente para la produccion de virus de influenza.
HK1062029B (en) Multiplication of viruses in a cell culture
HK1062030B (en) Methods for the industrial production of vaccines

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150618

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150618

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160902

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20160902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170531

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171012

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171109

R150 Certificate of patent or registration of utility model

Ref document number: 6243333

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250